GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

Diabetes Care

Volumn 20, Issue 12, 1997, Pages 1874-1879

  Gutniak, Mark K ^a,b,d   Larsson, Hillevi ^a   Sanders, Steven W ^b   Juneskans, Olof ^a   Holst, Jens J ^c   Ahren B O ^a  

^a LUND UNIVERSITY   (Sweden)

^b TheraTech Inc   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Vällingby Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; MALE; MOUTH MUCOSA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; STOMACH EMPTYING;

EID: 0030776130     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.12.1874     Document Type: Article

References (18)

1. Drucker DJ, Philippe J, Mojsov S, Chick W, Habener JF: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islets cell line. Proc Natl Acad Sci USA 84:3434-3438, 1987
2. Hoist JJ, Ørskov C, Vagn Nielsen O, Schwartz TW: Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174, 1987
3. Moisov S, Weir GC, Habener JF: Insulinotropin: glucagon-like peptide-1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616-619, 1987
4. Göke R, Wagner B, Fehmann HC, Göke B: Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med (Berlin) 193:97-103, 1993
5. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet ii:1300-1303, 1987
6. Fehmann HC, Göke R, Göke B: Glucagon-like peptide-1(7-37)/(7-36)amide is a new incretin. Mol Cell Endocrinol 85:C39-C44, 1992
7. Gutniak MK, Ørskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
8. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
9. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
10. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
11. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahrén B: Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 19:843-848, 1996
12. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539, 1994
13. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
14. Holst JJ, Bersani M: Assays for the peptide products of somatostatin gene expression. In Methods in Neurosciences. Conn PM, Ed. Academic, New York, 1991, p. 3-22
15. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1) (7-36)amide in type 2 (non-insulin- dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332, 1996
16. Ritzel R, Ørskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers: dose-response relationships. Diabetologia 38:720-725, 1995
17. Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S: Glucagon-like peptide 1 enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19:857-863, 1996
18. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ: Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44:626-630, 1995